Treating the First Portuguese Patient with Luxturna: A Small Step for World Science, a Giant Leap for Portuguese Ophthalmology

Authors

  • João Pedro Marques Department of Ophthalmology, Centro Hospitalar e Universitário de Coimbra (CHUC), Coimbra, Portugal; University Clinic of Ophthalmology, Faculty of Medicine, University of Coimbra (FMUC), Coimbra, Portugal; Clinical Academic Center of Coimbra (CACC), Coimbra, Portugal
  • Miguel Raimundo Department of Ophthalmology, Centro Hospitalar e Universitário de Coimbra (CHUC), Coimbra, Portugal; University Clinic of Ophthalmology, Faculty of Medicine, University of Coimbra (FMUC), Coimbra, Portugal; Clinical Academic Center of Coimbra (CACC), Coimbra, Portugal
  • Catarina Paiva Department of Ophthalmology, Centro Hospitalar e Universitário de Coimbra (CHUC), Coimbra, Portugal; University Clinic of Ophthalmology, Faculty of Medicine, University of Coimbra (FMUC), Coimbra, Portugal; Clinical Academic Center of Coimbra (CACC), Coimbra, Portugal
  • João Figueira Department of Ophthalmology, Centro Hospitalar e Universitário de Coimbra (CHUC), Coimbra, Portugal; University Clinic of Ophthalmology, Faculty of Medicine, University of Coimbra (FMUC), Coimbra, Portugal; Clinical Academic Center of Coimbra (CACC), Coimbra, Portugal
  • Mário Alfaite Department of Ophthalmology, Centro Hospitalar e Universitário de Coimbra (CHUC), Coimbra, Portugal; University Clinic of Ophthalmology, Faculty of Medicine, University of Coimbra (FMUC), Coimbra, Portugal; Clinical Academic Center of Coimbra (CACC), Coimbra, Portugal
  • Rufino Silva Department of Ophthalmology, Centro Hospitalar e Universitário de Coimbra (CHUC), Coimbra, Portugal; University Clinic of Ophthalmology, Faculty of Medicine, University of Coimbra (FMUC), Coimbra, Portugal; Clinical Academic Center of Coimbra (CACC), Coimbra, Portugal
  • Joaquim Murta Department of Ophthalmology, Centro Hospitalar e Universitário de Coimbra (CHUC), Coimbra, Portugal; University Clinic of Ophthalmology, Faculty of Medicine, University of Coimbra (FMUC), Coimbra, Portugal; Clinical Academic Center of Coimbra (CACC), Coimbra, Portugal

DOI:

https://doi.org/10.48560/rspo.24654

Keywords:

Gene therapy, Retinal Degeneration, Retinal Dystrophies

Downloads

Download data is not yet available.

References

Zhang WW, Li L, Li D, Liu J, Li X, Li W, et al. The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic. Hum Gene Ther. 2018;29:160-79. doi: 10.1089/hum.2017.218.

Maguire AM, Bennett J, Aleman EM, Leroy BP, Aleman TS. Clinical Perspective: Treating RPE65-Associated Retinal Dystrophy. Mol Ther. 2021 Feb 3;29(2):442-463. doi: 10.1016/j.ymthe.2020.11.029.

Maguire AM, Russell S, Wellman JA, Chung DC, Yu ZF, Tillman A, et al. Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials. Ophthalmology. 2019;126:1273-85. doi: 10.1016/j.ophtha.2019.06.017.

Johnson S, Buessing M, O'Connell T, Pitluck S, Ciulla TA. Cost-effectiveness of Voretigene Neparvovec-rzyl vs Standard Care for RPE65-Mediated Inherited Retinal Disease. JAMA Ophthalmol. 2019;137:1115-23. doi: 10.1001/jamaophthalmol.2019.2512.

Uhrmann MF, Lorenz B, Gissel C. Cost Effectiveness of Voretigene Neparvovec for RPE65-Mediated Inherited Retinal Degeneration in Germany. Transl Vis Sci Technol. 2020;9:17. doi: 10.1167/tvst.9.9.17.

Viriato D, Bennett N, Sidhu R, Hancock E, Lomax H, Trueman D, MacLaren RE. An Economic Evaluation of Voretigene Neparvovec for the Treatment of Biallelic RPE65-Mediated Inherited Retinal Dystrophies in the UK. Adv Ther. 2020;37:1233-47. doi: 10.1007/s12325-020-01243-y.

Zimmermann M, Lubinga SJ, Banken R, Rind D, Cramer G, Synnott PG, Chapman RH, Khan S, Carlson J. Cost Utility of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease. Value Health. 2019;22:161-7. doi: 10.1016/j.jval.2018.09.2841.

Redmond TM, Yu S, Lee E, Bok D, Hamasaki D, Chen N, et al. Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle. Nat Genet. 1998;20:344-51. doi: 10.1038/3813.

Lorenz B, Tavares J, van den Born LI, Marques JP, Scholl HPN; EVICR.net Group. Current management of patients with RPE65 mutation-associated inherited retinal degenerations (IRDs) in Europe. Results of a multinational survey by the European Vision Institute Clinical Research Network EVICR.net. Ophthalmic Res. 2021 (in press). doi: 10.1159/000515688.

Galvin O, Chi G, Brady L, Hippert C, Del Valle Rubido M, Daly A, et al. The Impact of Inherited Retinal Diseases in the Republic of Ireland (ROI) and the United Kingdom (UK) from a Cost-of-Illness Perspective. Clin Ophthalmol. 2020;14:707-19. doi: 10.2147/OPTH.S241928.

Pontikos N, Arno G, Jurkute N, Schiff E, Ba-Abbad R, Malka S, et al. Genetic Basis of Inherited Retinal Disease in a Molecularly Characterized Cohort of More Than 3000 Families from the United Kingdom. Ophthalmology. 2020;127:1384-94. doi: 10.1016/j.ophtha.2020.04.008.

Chung DC, Bertelsen M, Lorenz B, Pennesi ME, Leroy BP, Hamel CP, et al. The Natural History of Inherited Retinal Dystrophy Due to Biallelic Mutations in the RPE65 Gene. Am J Ophthalmol. 2019;199:58-70. doi: 10.1016/j.ajo.2018.09.024.

Pierrache LH, Ghafaryasl B, Khan MI, Yzer S, van Genderen MM, Schuil J, et al. Longitudinal Study of Rpe65-Associated Inherited Retinal Degenerations. Retina. 2020;40:1812-28. doi: 10.1097/IAE.0000000000002681.

Marques JP, Pires J, Costa J, Murta J, Silva R. Inherited Retinal Degenerations in Portugal: Addressing the Unmet Needs. Acta Med Port. 2021 (in press). doi: 10.20344/amp.15802.

Thompson DA, Ali RR, Banin E, Branham KE, Flannery JG, Gamm DM, et al; Monaciano Consortium. Advancing therapeutic strategies for inherited retinal degeneration: recommendations from the Monaciano Symposium. Invest Ophthalmol Vis Sci. 2015;56:918-31. doi: 10.1167/iovs.14-16049.

Marques JP, Carvalho AL, Henriques J, Murta JN, Saraiva J, Silva R. Design, development and deployment of a web-based interoperable registry for inherited retinal dystrophies in Portugal: the IRD-PT. Orphanet J Rare Dis. 2020;15:304. doi: 10.1186/s13023-020-01591-6.

Downloads

Published

2021-06-30

How to Cite

Marques, J. P., Raimundo, M., Paiva, C., Figueira, J., Alfaite, M., Silva, R., & Murta, J. (2021). Treating the First Portuguese Patient with Luxturna: A Small Step for World Science, a Giant Leap for Portuguese Ophthalmology. Revista Sociedade Portuguesa De Oftalmologia, 45(2), 67–69. https://doi.org/10.48560/rspo.24654

Issue

Vol. 45 No. 2 (2021)

Section

Original Article

License

CC BY

Do not forget to download the Authorship responsibility statement/Authorization for Publication and Conflict of Interest.
The article can only be submitted with these two documents.
To obtain the Authorship responsibility statement/Authorization for Publication file, click here.

To obtain the Conflict of Interest file (ICMJE template), click here